Atenção: Todas as denúncias são sigilosas e sua identidade será preservada.
Os campos nome e e-mail são de preenchimento opcional
Metadados | Descrição | Idioma |
---|---|---|
Autor(es): dc.contributor.author | OLIVEIRA, ALESSANDRA MOREIRA DE | - |
Autor(es): dc.contributor.author | LIMA, LEANDRO GABRIEL RIBEIRO DE | - |
Autor(es): dc.contributor.author | ESTRELA, RITA DE CÁSSIA ELIAS | - |
Data de aceite: dc.date.accessioned | 2022-12-22T12:32:28Z | - |
Data de disponibilização: dc.date.available | 2022-12-22T12:32:28Z | - |
Data de envio: dc.date.issued | 2022-10-20 | - |
Fonte: dc.identifier.uri | http://educapes.capes.gov.br/handle/capes/718979 | - |
Resumo: dc.description.abstract | To evaluate misoprostol (prostaglandin E1 analog ) use profile in hospital unit in the scope of Brazilian Public Health through the Unified Health System (SUS), misoprostol is dispensed as a vaginal tablet. It is part of the basic component of Pharmaceutical Assistance and its dispensation is restricted to Brazilian hospitals. Methods:The study was observational, retrospective, descriptive and quantitative whose main objective was to describe the use of this drug in the hospital scenario and was performed in a medium-sized hospital in the Metropolitan Region II of Rio de Janeiro. Data (from July 2017 to July 2018) were obtained from the dispensation forms of misoprostol. The medical prescriptions or patient charts were not evaluated. The medical prescriptions or patient charts were not evaluated. All dispensations using misoprostol 25 μg or misoprostol 200 μg, regardless of indication, were included in the study. Meanwhile, these ones where two presentations were prescribed, were excluded. Results: It was observed that the main indications of misoprostol 25 µg and misoprostol 200 µg were induction of labor (47.8 %); induction of abortion (43,9 %) and prevention of hemorrhage (5,5 %), all recommended by the International Federation of Obstetrics and Gynecology (FIGO). For induction of labor, in 46.2% of the forms were requested misoprostol 25 μg, against only 1.6% for misoprostol 200 μg. For induction of abortion and prevention of hemorrhage, respectively, misoprostol 25 μg and 200 μg were obtained: 4.4%; 35.7% and 0.5%; 4.9%. The use of misoprostol 200 μg for uterine hypertrophy and anembryonic gestation resulted in the lowest values in terms of indication, 0.5% and 1.1%, respectively. Conclusion: misoprostol use profile in a hospital unit was an important tool to understand the use of this drug in a Brazilian Hospital aiming at improving the quality of services provided by hospital pharmacy. | pt_BR |
Idioma: dc.language.iso | en | pt_BR |
Palavras-chave: dc.subject | Misoprostol | pt_BR |
Título: dc.title | Misoprostol Use Profile in a Public Hospital in Rio de Janeiro/Brazil: From the Perspective of a Hospital Pharmacy Dispensation (Atena Editora) | pt_BR |
Tipo de arquivo: dc.type | livro digital | pt_BR |
Aparece nas coleções: | Laboratórios |
Arquivos associados: | ||||
---|---|---|---|---|
misoprostol-use-profile-in-a-public-hospital-in-.pdf | 864 kB | Adobe PDF | /bitstream/capes/718979/1/misoprostol-use-profile-in-a-public-hospital-in-.pdfDownload |
O Portal eduCAPES é oferecido ao usuário, condicionado à aceitação dos termos, condições e avisos contidos aqui e sem modificações. A CAPES poderá modificar o conteúdo ou formato deste site ou acabar com a sua operação ou suas ferramentas a seu critério único e sem aviso prévio. Ao acessar este portal, você, usuário pessoa física ou jurídica, se declara compreender e aceitar as condições aqui estabelecidas, da seguinte forma: